Qiu Lingbing, Ma Tianyi, Guo Yunmiao, Chen Jugao
Department of Oncology, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, 518020, Shenzhen, Guangdong Province, P. R. China.
Clinical Research Institute of Zhanjiang, Central People's Hospital of Zhanjiang, Guangdong Medical University Zhanjiang Central Hospital, 236 Yuanzhu Road, 524045, Zhanjiang, Guangdong Province, P. R. China.
Open Med (Wars). 2024 Jul 30;19(1):20240999. doi: 10.1515/med-2024-0999. eCollection 2024.
This study aims to address the substantive issue of lacking reliable prognostic biomarkers in hepatocellular carcinoma (HCC) by investigating the relationship between TP53-inducible glycolysis and apoptosis regulator (TIGAR) and HCC prognosis using The Cancer Genome Atlas database.
(1) Integrated statistical analyses, including logistic regression, Wilcoxon signed-rank test, and Kruskal-Wallis test, were conducted to explore the association between TIGAR expression and clinical-pathological features of HCC. (2) The Kaplan-Meier method combined with univariate and multivariate Cox regression models underscored TIGAR as a prognostic factor in HCC. (3) Gene set enrichment analysis (GSEA) revealed key pathways associated with TIGAR, while single-sample gene set enrichment analysis (ssGSEA) determined its relevance to cancer immune infiltration.
(1) Elevated TIGAR expression was significantly correlated with decreased survival outcomes in HCC patients. (2) GSEA highlighted the significant link between TIGAR and humoral immunity. (3) ssGSEA revealed a positive correlation between TIGAR expression and infiltration of Th1 and Th2 cells and a negative correlation with Th17 cell infiltration.
TIGAR, as a potential prognostic biomarker for HCC, holds significant value in immune infiltration. Understanding the role of TIGAR could contribute to improved prognostic predictions and personalized treatment strategies for HCC patients.
本研究旨在通过使用癌症基因组图谱数据库研究TP53诱导的糖酵解和凋亡调节因子(TIGAR)与肝细胞癌(HCC)预后之间的关系,以解决HCC中缺乏可靠预后生物标志物这一实质性问题。
(1)进行综合统计分析,包括逻辑回归、Wilcoxon符号秩检验和Kruskal-Wallis检验,以探讨TIGAR表达与HCC临床病理特征之间的关联。(2)Kaplan-Meier方法结合单变量和多变量Cox回归模型强调TIGAR是HCC的一个预后因素。(3)基因集富集分析(GSEA)揭示了与TIGAR相关的关键途径,而单样本基因集富集分析(ssGSEA)确定了其与癌症免疫浸润的相关性。
(1)HCC患者中TIGAR表达升高与生存结果降低显著相关。(2)GSEA突出了TIGAR与体液免疫之间的显著联系。(3)ssGSEA显示TIGAR表达与Th1和Th2细胞浸润呈正相关,与Th17细胞浸润呈负相关。
TIGAR作为HCC的一种潜在预后生物标志物,在免疫浸润方面具有重要价值。了解TIGAR的作用有助于改善HCC患者的预后预测和个性化治疗策略。